The preclinical landscape is undergoing a paradigm shift with the emergence of "New Approach Methodologies" (NAMs). Driven by the FDA Modernization Act 2.0, there is a growing push to reduce or replace traditional animal testing with alternative models. "Organ-on-a-Chip" (OOC) technology—microfluidic devices lined with living human cells—allows CROs to simulate the physiological environment of human organs, such as the liver or heart, with higher predictive accuracy than animal models.

In silico (computer-based) modeling is also playing a larger role. Using AI and machine learning, preclinical CROs can screen thousands of compounds for potential toxicity before a single physical experiment is conducted. Technical reports on the adoption of these digital and micro-physiological systems are detailed in the Preclinical CRO Market industry analysis. These technologies are particularly useful for "Lead Optimization," where small changes in a molecule's structure can be evaluated for their impact on safety and efficacy.

While animal models remain a regulatory requirement for many types of safety data, the hybrid use of OOC and AI is shortening the discovery timeline. These "human-relevant" models are especially critical for testing modern modalities like cell and gene therapies, where the biological response in animals often fails to accurately mirror the complex immune response or genomic integration that occurs in human patients.